Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?

Table 5 Percentage of patients achieving target values according to therapy group

	SGLT-2i	GLP-1RA	Simultaneous	Chi-square	P value
HbA1c
< 7%	51.7	47.9	47.4	0.156	0.925
> 7%	48.3	52.1	52.6
Total	100.0	100.0	100.0
FPG
< 7 mmol	70.6	30.0	54.5	7.748	0.021
> 7 mmol	29.4	70.0	45.5
Total	100.0	100.0	100.0
PPG
< 10 mmol	90.0	84.4	72.7	2.775	0.250
> 10 mmol	10.0	15.6	27.3
Total	100.0	100.0	100.0
eGFR
> 60 mL/min per 1.73 m2	90.9	80.8	86.0	1.008	0.604
< 60 mL/min per 1.73 m2	9.1	19.2	14.0
Total	100.0	100.0	100.0
LDL
< 1.8 mmol	16.7	21.6	29.5	1.571	0.456
> 1.8 mmol	83.3	78.4	70.5
Total	100.0	100.0	100.0
LDL
< 2.5 mmol	66.7	54.1	52.3	1.413	0.493
> 2.5 mmol	33.3	45.9	47.7
Total	100.0	100.0
Weight loss > 5%
No	58.6	52.3	33.3	6.232	0.044
Yes	41.4	47.7	66.7
Total	100.0	100.0	100.0

BMI: Body mass index; eGFR: Estimated glomerular filtration rate; FPG: Fasting plasma glucose; GLP-1RA: Glucagon-like-polypeptide-1 receptor agonist; HbA1c: Hemoglobin A1c; LDL: Low-density lipoprotein cholesterol; PPG: Prandial plasma glucose; SGLT-2i: Sodium/glucose cotransporter-2 inhibitors.